Advances and prospects in tumor infiltrating lymphocyte therapy
Abstract Tumor-infiltrating lymphocyte (TIL) therapy in adoptive T-cell therapy (ACT) has already caused durable regression in a variety of cancer types due to T-cell persistence, clinical activity, and duration of objective response and safety. TILs are composed of polyclonal effector T-cells speci...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2024-11-01
|
| Series: | Discover Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s12672-024-01410-5 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850061897695494144 |
|---|---|
| author | Xu Qiu Shengjun Li Tianyu Fan Yue Zhang Bin Wang Bei Zhang Mingzhe Zhang Li Zhang |
| author_facet | Xu Qiu Shengjun Li Tianyu Fan Yue Zhang Bin Wang Bei Zhang Mingzhe Zhang Li Zhang |
| author_sort | Xu Qiu |
| collection | DOAJ |
| description | Abstract Tumor-infiltrating lymphocyte (TIL) therapy in adoptive T-cell therapy (ACT) has already caused durable regression in a variety of cancer types due to T-cell persistence, clinical activity, and duration of objective response and safety. TILs are composed of polyclonal effector T-cells specific to heterogenetic tumor antigens, reasonably providing a promising means for tumor therapy. In addition, their expansion in vitro can release them from the suppressive tumor microenvironment. Even though significant advances have been made in the procedure of TIL therapy, from TIL isolation, modification, expansion, and infusion back to the patient to target the tumor, strategy optimization is always ongoing to overcome drawbacks such as a complex process, options for the lineage differentiation status of TILs, and sufficient trafficking of TILs to the tumor. In this review, we summarize the current advances of TIL therapy, raise problem-based optimization strategies, and provide future perspectives on next-generation TIL therapy as a potential avenue for enhancing cell-based immunotherapy. |
| format | Article |
| id | doaj-art-9ea2ea92a91e4eacbebc1cd27cde25f4 |
| institution | DOAJ |
| issn | 2730-6011 |
| language | English |
| publishDate | 2024-11-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-9ea2ea92a91e4eacbebc1cd27cde25f42025-08-20T02:50:04ZengSpringerDiscover Oncology2730-60112024-11-0115111810.1007/s12672-024-01410-5Advances and prospects in tumor infiltrating lymphocyte therapyXu Qiu0Shengjun Li1Tianyu Fan2Yue Zhang3Bin Wang4Bei Zhang5Mingzhe Zhang6Li Zhang7The Department of Immunology, School of Basic Medicine, Qingdao UniversityClinical Laboratory, Qingdao Women and Children’s HospitalThe Department of Immunology, School of Basic Medicine, Qingdao UniversityThe Department of Immunology, School of Basic Medicine, Qingdao UniversityThe Department of Pathogenic Biology, School of Basic Medicine, Qingdao UniversityThe Department of Immunology, School of Basic Medicine, Qingdao UniversityThe Cancer Institute, The Affiliated Hospital of Qingdao UniversityThe Department of Immunology, School of Basic Medicine, Qingdao UniversityAbstract Tumor-infiltrating lymphocyte (TIL) therapy in adoptive T-cell therapy (ACT) has already caused durable regression in a variety of cancer types due to T-cell persistence, clinical activity, and duration of objective response and safety. TILs are composed of polyclonal effector T-cells specific to heterogenetic tumor antigens, reasonably providing a promising means for tumor therapy. In addition, their expansion in vitro can release them from the suppressive tumor microenvironment. Even though significant advances have been made in the procedure of TIL therapy, from TIL isolation, modification, expansion, and infusion back to the patient to target the tumor, strategy optimization is always ongoing to overcome drawbacks such as a complex process, options for the lineage differentiation status of TILs, and sufficient trafficking of TILs to the tumor. In this review, we summarize the current advances of TIL therapy, raise problem-based optimization strategies, and provide future perspectives on next-generation TIL therapy as a potential avenue for enhancing cell-based immunotherapy.https://doi.org/10.1007/s12672-024-01410-5Tumor infiltrating lymphocyte (TIL)T-cellsAdoptive cell therapy (ACT)ImmunotherapyTumor treatment |
| spellingShingle | Xu Qiu Shengjun Li Tianyu Fan Yue Zhang Bin Wang Bei Zhang Mingzhe Zhang Li Zhang Advances and prospects in tumor infiltrating lymphocyte therapy Discover Oncology Tumor infiltrating lymphocyte (TIL) T-cells Adoptive cell therapy (ACT) Immunotherapy Tumor treatment |
| title | Advances and prospects in tumor infiltrating lymphocyte therapy |
| title_full | Advances and prospects in tumor infiltrating lymphocyte therapy |
| title_fullStr | Advances and prospects in tumor infiltrating lymphocyte therapy |
| title_full_unstemmed | Advances and prospects in tumor infiltrating lymphocyte therapy |
| title_short | Advances and prospects in tumor infiltrating lymphocyte therapy |
| title_sort | advances and prospects in tumor infiltrating lymphocyte therapy |
| topic | Tumor infiltrating lymphocyte (TIL) T-cells Adoptive cell therapy (ACT) Immunotherapy Tumor treatment |
| url | https://doi.org/10.1007/s12672-024-01410-5 |
| work_keys_str_mv | AT xuqiu advancesandprospectsintumorinfiltratinglymphocytetherapy AT shengjunli advancesandprospectsintumorinfiltratinglymphocytetherapy AT tianyufan advancesandprospectsintumorinfiltratinglymphocytetherapy AT yuezhang advancesandprospectsintumorinfiltratinglymphocytetherapy AT binwang advancesandprospectsintumorinfiltratinglymphocytetherapy AT beizhang advancesandprospectsintumorinfiltratinglymphocytetherapy AT mingzhezhang advancesandprospectsintumorinfiltratinglymphocytetherapy AT lizhang advancesandprospectsintumorinfiltratinglymphocytetherapy |